Pegloticase

From Wikipedia, the free encyclopedia - View original article

Pegloticase
Clinical data
Trade namesKrystexxa
AHFS/Drugs.commonograph
MedlinePlusa611015
Licence dataUS FDA:link
Pregnancy cat.
Legal status
RoutesIntravenous
Pharmacokinetic data
BioavailabilityN/A
Half-life10–12 days
Identifiers
CAS number885051-90-1 N
ATC codeM04AX02
UNIIR581OT55EA YesY
KEGGD09316 YesY
ChEMBLCHEMBL1237025 N
Chemical data
FormulaC1549H2430N408O448S8 (peptide monomer)
Molecular mass497 kDa (polymer-modified tetramer)
 N (what is this?)  (verify)
 
Jump to: navigation, search
Pegloticase
Clinical data
Trade namesKrystexxa
AHFS/Drugs.commonograph
MedlinePlusa611015
Licence dataUS FDA:link
Pregnancy cat.
Legal status
RoutesIntravenous
Pharmacokinetic data
BioavailabilityN/A
Half-life10–12 days
Identifiers
CAS number885051-90-1 N
ATC codeM04AX02
UNIIR581OT55EA YesY
KEGGD09316 YesY
ChEMBLCHEMBL1237025 N
Chemical data
FormulaC1549H2430N408O448S8 (peptide monomer)
Molecular mass497 kDa (polymer-modified tetramer)
 N (what is this?)  (verify)

Pegloticase (trade name Krystexxa, formerly Puricase)[1] is a drug for the treatment of severe, treatment-refractory, chronic gout, developed by Savient Pharmaceuticals.[2][3]

In September 2010, the FDA approved pegloticase for marketing in the United States after two clinical trials demonstrated the drug lowered uric acid levels and reduced deposits of uric acid crystals in joints and soft tissue. The European Medicines Agency (EMA) granted marketing authorization in January 2013 for treatment of disabling tophaceous gout. Pegloticase is the first drug approved for this indication. Krystexxa is currently marketed in the U.S. by Crealta Pharmaceuticals LLC.

The drug is administered by infusion intravenously under the direction of a rheumatologist.

Medical uses[edit]

It is an option for the 3% of people who are intolerant to other medications.[4] Pegloticase is give as an intravenous infusion every two weeks,[4] and has been found to reduce uric acid levels in this population.[5] It is likely useful for tophi but has a high rate of side effects.[6]

Side effects[edit]

Pegloticase may show immunogenicity.[7]

Mechanism of action[edit]

Pegloticase is a recombinant porcine-like uricase. Similarly to rasburicase, it metabolises uric acid to allantoin. This reduces the risk of precipitates, since allantoin is five to ten times more soluble than uric acid.

In contrast to rasburicase, pegloticase is pegylated to increase its elimination half-life from about eight hours to ten or twelve days, and to decrease the immunogenicity of the foreign uricase protein. This modification allows for an application just once every two to four weeks, making this drug suitable for long-term treatment.[8]

Chemistry[edit]

Pegloticase is a tetrameric peptide composed of four identical chains of about 300 amino acids each. Approximately nine of the 30 lysine residues in each chain are pegylated. These side chains consist of about 225 ethylene glycol units each.[2]

See also[edit]

PEGylation

References[edit]

  1. ^ Savient to Present Multiple Abstracts At the European League Against Rheumatism (EULAR) 2009 Annual Congress
  2. ^ a b Statement on a nonproprietary name adopted by the USAN Council
  3. ^ Savient Pharmaceuticals: Uricase
  4. ^ a b "FDA approves new drug for gout". FDA. September 14, 2010. 
  5. ^ Sundy, JS; Baraf, HS, Yood, RA, Edwards, NL, Gutierrez-Urena, SR, Treadwell, EL, Vázquez-Mellado, J, White, WB, Lipsky, PE, Horowitz, Z, Huang, W, Maroli, AN, Waltrip RW, 2nd, Hamburger, SA, Becker, MA (Aug 17, 2011). "Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials". JAMA: the Journal of the American Medical Association 306 (7): 711–20. doi:10.1001/jama.2011.1169. PMID 21846852. 
  6. ^ Sriranganathan, MK; Vinik, O; Bombardier, C; Edwards, CJ (Oct 20, 2014). "Interventions for tophi in gout.". The Cochrane database of systematic reviews 10: CD010069. PMID 25330136. 
  7. ^ Abraham J. Domb, Neeraj Kumar (2 August 2011). Biodegradable Polymers in Clinical Use and Clinical Development. John Wiley & Sons. 
  8. ^ Biggers, K; Scheinfeldt, N (2008). Current Opinion in Investigational Drugs 9 (4): 422–429. 

External links[edit]